However, the benefits of immunotherapy in patients with advanced NSCLC remain modest, with response rates (RR) of 30–45%, 5-year survival rate of 13–32%, depending on programmed death ligand one (PD-L1) levels, when immunotherapy is administered as a single agent [7,8]. Here, CD274 is linked to non-small cell lung carcinoma.